Research and Markets: EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/xt5qrd/epicast_report) has announced the addition of the "EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023" report to their offering.

The epidemiology of ACS in the 7MM has changed significantly during the past two decades and varies between the western and Japanese markets. In order to capture the country-specific trends and provide detailed patient population segmentation, The publisher epidemiologists built separate forecasts for (myocardial infarction) (MI) and UA in the 7MM and used a case-flow methodology to determine the number of cases that survived until hospital discharge and for one year after hospital discharge.

The publisher epidemiologists forecast that in the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2013 to 1.47 million cases in 2023 at the rate of 1.40% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages =65 years (69.34%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market.

Scope

  • The ACS EpiCast Report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2013 to 2023 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
  • Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
  • ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
  • ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
  • Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2013 to 2023 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)
  • The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global Trends - MI

3.4 Global Trends - UA

3.5 Forecast Methodology

3.6 Epidemiological Forecast for ACS (2013-2023) - Hospitalized Incident Cases

3.7 Epidemiological Forecast for MI (2013-2023) - Prevalent Cases

3.8 Discussion

4 Appendix

For more information visit http://www.researchandmarkets.com/research/xt5qrd/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular